Cannabidiol potentiates p53-driven autophagic cell death in non-small cell lung cancer following DNA damage: a novel synergistic approach beyond canonical pathways DOI Creative Commons
Youngsic Jeon, Taejung Kim,

Hyukjoon Kwon

и другие.

Experimental & Molecular Medicine, Год журнала: 2025, Номер unknown

Опубликована: Май 1, 2025

The search for more effective and safer cancer therapies has led to an increasing interest in combination treatments that use well-established agents. Here we explore the potential of cannabidiol (CBD), a compound derived from cannabis, enhance anticancer effects etoposide non-small cell lung (NSCLC). Although CBD is primarily used manage childhood epilepsy, its broader therapeutic applications are being actively investigated, particularly oncology. Our results revealed that, among various tested chemotherapeutic drugs, showed most significant reduction NSCLC viability when combined with CBD. To understand this synergistic effect, conducted extensive transcriptomic proteomic profiling, which upregulated genes associated autophagic death while downregulating key oncogenes known drive tumor progression. This dual effect on oncogene suppression was mediated by inactivation PI3K-AKT-mTOR signaling pathway, crucial regulator growth survival, found be dependent p53 status. Interestingly, our analysis therapy did not rely traditional cannabinoid receptors or transient receptor cation channels, indicating exerts through novel, noncanonical mechanisms. findings suggest could represent groundbreaking approach treatment, cases where conventional fail. By inducing inhibiting oncogenic pathways, strategy offers promising new avenue enhancing treatment efficacy NSCLC, especially tumors function.

Язык: Английский

mTOR: Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process DOI Open Access
Sulaiman K. Marafie, Fahd Al‐Mulla, Jehad Abubaker

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(11), С. 6141 - 6141

Опубликована: Июнь 2, 2024

The mammalian target of rapamycin (mTOR) is a pivotal regulator, integrating diverse environmental signals to control fundamental cellular functions, such as protein synthesis, cell growth, survival, and apoptosis. Embedded in complex network signaling pathways, mTOR dysregulation implicated the onset progression range human diseases, including metabolic disorders diabetes cardiovascular well various cancers. also has notable role aging. Given its extensive biological impact, prime therapeutic for addressing these conditions. development inhibitors proven advantageous numerous research domains. This review delves into significance signaling, highlighting critical components this intricate that contribute disease. Additionally, it addresses latest findings on their clinical implications. emphasizes importance developing more effective next-generation with dual functions efficiently pathways. A comprehensive understanding will enable strategies managing diseases associated dysregulation.

Язык: Английский

Процитировано

21
Molecular principles underlying aggressive cancers DOI Creative Commons
Ruth Nussinov, Bengi Ruken Yavuz, Hyunbum Jang

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Фев. 16, 2025

Язык: Английский

Процитировано

3
LncRNA TCL6 regulates miR-876–5p/MYL2 axis to suppress breast cancer progression DOI

Yaobang Liu,

Haipeng Li,

Dahai Chai

и другие.

Translational Oncology, Год журнала: 2025, Номер 53, С. 102210 - 102210

Опубликована: Янв. 27, 2025

Язык: Английский

Процитировано

2
Divide and Conquer—Targeted Therapy for Triple-Negative Breast Cancer DOI Open Access
Milica Nedeljković, Ana Vuletić, Katarina Mirjačić Martinović

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(4), С. 1396 - 1396

Опубликована: Фев. 7, 2025

Triple-negative breast cancer (TNBC) is the most aggressive and malignant type of with limited treatment options poor prognosis. One significant impediments in TNBC high heterogeneity this disease, as highlighted by detection several molecular subtypes TNBC. Each subtype driven distinct mutations pathway aberrations, giving rise to specific characteristics closely connected clinical behavior, outcomes, drug sensitivity. This review summarizes knowledge regarding how it can be harnessed devise tailored strategies instead blindly using targeted drugs. We provide an overview novel agents key insights about new modalities emphasis on androgen receptor signaling pathway, stem cell-associated pathways, phosphatidylinositol 3-kinase (PI3K)/AKT growth factor signaling, immunotherapy.

Язык: Английский

Процитировано

1
Discovery of 5-Phenylthiazol-2-amine Derivatives as Novel PI4KIIIβ Inhibitors with Efficacious Antitumor Activity by Inhibiting the PI3K/AKT Axis DOI

Bichuan Wang,

Siyuan Hao, Fang Han

и другие.

Journal of Medicinal Chemistry, Год журнала: 2025, Номер unknown

Опубликована: Март 6, 2025

To develop novel PI4KIIIβ inhibitors and explore their antitumor activity, a series of 5-phenylthiazol-2-amine derivatives were synthesized by structural modifications PIK93. Biological assay results indicated that compounds 16 43 exhibited superior selective inhibitory antiproliferative activity than Mechanistic studies revealed the two inhibit PI3K/AKT pathway more effectively, thereby inducing cancer cell apoptosis, cycle arrest in G2/M phase autophagy. Importantly, vivo toxicity pharmacodynamics showed safety to commercially available axis inhibitor alpelisib, obviously small lung H446 xenograft models. Overall, this work highlights therapeutic potential treatment tumors, provides candidates viable drug development strategies for inhibitors.

Язык: Английский

Процитировано

1
The Comprehensive Analysis of Weighted Gene Co-Expression Network Analysis and Machine Learning Revealed Diagnostic Biomarkers for Breast Implant Illness Complicated with Breast Cancer DOI Creative Commons
Zhenfeng Huang, Huibo Wang, Hui Pang

и другие.

Breast Cancer Targets and Therapy, Год журнала: 2025, Номер Volume 17, С. 305 - 324

Опубликована: Апрель 1, 2025

An increasing number of breast cancer (BC) patients choose prosthesis implantation after mastectomy, and the occurrence implant illness (BII) has received attention underlying molecular mechanisms have not been clearly elucidated. This study aimed to identify crosstalk genes between BII BC explored their clinical value mechanism initially. We retrieved data from Gene Expression Omnibus (GEO) The Cancer Genome Atlas (TCGA), identified differentially expressed (DEG) as well module using Limma weighted gene co-expression network analysis (WGCNA). Enrichment analysis, protein-protein interaction (PPI), machine learning algorithms were performed explore hub genes. employed a nomogram receiver operating characteristic curve evaluate diagnostic accuracy. Single-cell disclosed variations in expression key across distinct cellular populations. levels further confirmed cell lines. Immunohistochemical was utilized examine protein 25 with undergoing prosthetic surgery. Ultimately, we deployed single-sample Set Analysis (ssGSEA) scrutinize immunological profiles normal cohorts, non-BII groups. WGCNA 1137 common genes, whereas DEG found 541 overlapping BC. After constructing PPI network, 17 selected, three potential include KRT14, KIT, ALB chosen for creation assessment through learning. validation these results conducted by examining patterns dataset, lines, BII-BC patients. However, ssGSEA uncovered different immune infiltration pinpointed shared central pathways Shedding light on complex conditions suggesting targets therapeutic strategies.

Язык: Английский

Процитировано

1
Scaffold Hopping Method for Design and Development of Potential Allosteric AKT Inhibitors DOI
Alireza Poustforoosh

Molecular Biotechnology, Год журнала: 2024, Номер unknown

Опубликована: Окт. 27, 2024

Язык: Английский

Процитировано

7
Next-generation biomarkers for prognostic and potential therapeutic enhancement in Triple negative breast cancer DOI

Risav Banerjee,

Indrajit Maitra,

T. Bhattacharya

и другие.

Critical Reviews in Oncology/Hematology, Год журнала: 2024, Номер 201, С. 104417 - 104417

Опубликована: Июнь 18, 2024

Язык: Английский

Процитировано

6
Decoding multiple sclerosis: Unravelling the complexities of pathogenesis, progression, mechanisms and therapeutic innovations DOI

Syeda Rida Zainab,

Jehanzeb Khan, Muhammad Khalid Tipu

и другие.

Neuroscience, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Язык: Английский

Процитировано

3
Application of Gene Editing in Triple‐Negative Breast Cancer Research DOI
Shuying Feng, Jixia Li, Aifen Yan

и другие.

Cell Biochemistry and Function, Год журнала: 2025, Номер 43(1)

Опубликована: Янв. 1, 2025

ABSTRACT With the rapid development of gene editing technology, its application in breast cancer has gradually become focus research. This article reviews technology treatment cancer, and discusses challenges future directions. The key areas will be outlined, including discovery new therapeutic targets drugs related to pathway. Gene played an important role targets. Through use cancer‐related genes are systematically edited regulate regulatory factors on pathways or tumor suppressor such as FOXC1 BRCA , results analyzed cell animal experiments, target is obtained from experimental results, which provides clues for drugs. approach innovative way find more effective strategies inhibit growth. In addition, also promoted personalization treatment. By analyzing a patient's genomic information, researchers can pinpoint genetic mutations design personalized treatments. expected improve effect reduce adverse reactions. Finally, support immunotherapy. immune cells make them potent against tumors, trying develop immunotherapies bring options patients.

Язык: Английский

Процитировано

0